Pfizer’s Ibrance fails to meet primary endpoint in early breast cancer trial
This article was originally published here
The phase 3 PENELOPE-B trial has failed to achieve the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative
The post Pfizer’s Ibrance fails to meet primary endpoint in early breast cancer trial appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!